<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30468" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Transfusion Transmitted Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Justiz Vaillant</surname>
            <given-names>Angel A.</given-names>
          </name>
          <aff>University of the West Indies</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zubair</surname>
            <given-names>Muhammad</given-names>
          </name>
          <aff>Indus Hospital &#x00026; Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sticco</surname>
            <given-names>Kristin L.</given-names>
          </name>
          <aff>Stony Brook University Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Angel Justiz Vaillant declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Zubair declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristin Sticco declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30468.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Transfusion-transmitted diseases pose a significant concern in the medical community, with nearly 119 million blood donations collected worldwide each year and approximately 5 million Americans requiring blood transfusions annually. Despite advancements in testing methodologies, donated blood products remain a potential source of bacterial, viral, and parasitic transmission. The most critical risk factor arises during the donor's window period when antibody and antigen levels are too low to be detected by current screening methods. Additionally, the risk of acquiring infection from blood products is influenced by the recipient's geographical location, immune status, and the country's capacity to screen for infectious agents.</p>
        <p>This activity addresses the complexities surrounding transfusion-dependent diseases, emphasizing&#x000a0;donor selection and adherence to stringent screening protocols to mitigate risks. This activity discusses the potential etiologies of transfusion-transmitted diseases, their epidemiology, clinical manifestations, management, and prevention, and how to differentiate them from other acute transfusion reactions. Additionally, this activity presents how the interprofessional healthcare team and regulatory bodies can implement best practices to ensure the safety of the blood supply and improve patient outcomes.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Apply current guidelines for screening blood products to prevent transfusion-transmitted diseases.</p></list-item><list-item><p>Differentiate between various transfusion-transmitted pathogens and determine appropriate interventions.</p></list-item><list-item><p>Implement evidence-based practices to improve the overall safety of blood transfusions.</p></list-item><list-item><p>Collaborate with interdisciplinary team members to establish comprehensive protocols for transfusion safety.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30468&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30468">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30468.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Annually, nearly 5 million Americans undergo blood transfusions for&#x000a0;various medical conditions&#x000a0;such as&#x000a0;acute blood loss, surgery, hemophilia, or cancer.<xref ref-type="bibr" rid="article-30468.r1">[1]</xref>&#x000a0;In the US alone, approximately 29,000 red blood cell&#x000a0;(RBC) units, 5,000 platelets, and 6,500 plasma units are utilized daily.&#x000a0;While the&#x000a0;risk of transfusion-transmitted diseases (TTD) is extremely low, it persists primarily due to "window-period" donations, where antibodies and antigens remain undetectable by current screening techniques. Furthermore, the blood product supply may be&#x000a0;susceptible to contamination by unidentified human pathogens.</p>
        <p>Blood products used in transfusions can&#x000a0;carry bacterial, viral, and parasitic pathogens. Among these, the&#x000a0;risk&#x000a0;of transfusion-transmitted bacterial infections (TTBI)&#x000a0;exceeds that of transfusion-transmitted viral infections, with platelet transfusion posing the highest risk of TTBI. Viral organisms commonly transmitted through blood transfusions include HIV, hepatitis C (HCV), hepatitis B (HBV), hepatitis A (HAV), West Nile virus (WNV), cytomegalovirus (CMV), severe acute respiratory syndrome coronavirus (SARS-CoV-1), human T-cell lymphotropic viruses (HTLV), Zika virus, and parvovirus B19.<xref ref-type="bibr" rid="article-30468.r2">[2]</xref></p>
        <p>Prions&#x000a0;responsible for Creutzfeldt-Jakob disease (CJD) and protozoa&#x000a0;from the&#x000a0;<italic toggle="yes">Plasmodium</italic>&#x000a0;genus,&#x000a0;which causes malaria, are additional potential pathogens. Ongoing enhancements in infectious disease assays, meticulous donor screening, and pathogen inactivation methods&#x000a0;contribute to enhancing&#x000a0;the safety of the blood supply. Persistent&#x000a0;vigilance is&#x000a0;crucial to address emerging pathogens and&#x000a0;refine current screening practices.</p>
      </sec>
      <sec id="article-30468.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of TTBI typically involves the introduction of bacteria into the bloodstream through contaminated blood products during transfusion.&#x000a0;Bacterial contamination can occur at various stages, including during blood collection, processing, storage, or transfusion. Common sources of bacterial contamination include skin flora, collection or storage equipment contamination, and improper handling procedures.&#x000a0;The spectrum of pathogenic organisms varies based on the collected blood product.<xref ref-type="bibr" rid="article-30468.r3">[3]</xref></p>
        <p>
<bold>Bacterial Organisms</bold>
</p>
        <p>Blood collection&#x000a0;banks typically store units of&#x000a0;RBCs between 34 to 43 &#x000b0;F (1 to 6 &#x000b0;C), favoring the growth of gram-negative rods.<xref ref-type="bibr" rid="article-30468.r4">[4]</xref>&#x000a0;The most frequently reported bacterial organisms encountered in units of&#x000a0;RBCs are&#x000a0;<italic toggle="yes">Yersinia enterocolitica,</italic>&#x000a0;notably associated with sepsis secondary to red blood cell transfusion. Other commonly reported organisms include <italic toggle="yes">Pseudomonas</italic>&#x000a0;<italic toggle="yes">fluorescens</italic>,&#x000a0;<italic toggle="yes">Enterobacter</italic>,<italic toggle="yes">&#x000a0;Serratia</italic>, and<italic toggle="yes">&#x000a0;Escherichia coli</italic>. However,&#x000a0;<italic toggle="yes">Babesia microti</italic>&#x000a0;has emerged as the most frequently associated organism with&#x000a0;fatalities after&#x000a0;RBC transfusion.<xref ref-type="bibr" rid="article-30468.r5">[5]</xref></p>
        <p>Platelet products stored at room temperature, typically&#x000a0;between 68 to 75 &#x000b0;F (20 to 24 &#x000b0;C), carry the highest risk of bacterial contamination among blood products.<xref ref-type="bibr" rid="article-30468.r6">[6]</xref>&#x000a0;Gram-positive bacteria are more commonly found in platelet products. The most prevalent bacterial pathogens isolated from platelet products are&#x000a0;<italic toggle="yes">Streptococcus viridans, Streptococcus bovis,&#x000a0;</italic>and beta-hemolytic streptococci<italic toggle="yes">&#x000a0;</italic>with an incidence of 39% to 48%, coagulase-negative staphylococcus<italic toggle="yes">&#x000a0;</italic>with an incidence of 21% to 24%, and&#x000a0;<italic toggle="yes">Staphylococcus</italic>&#x000a0;<italic toggle="yes">aureus</italic>&#x000a0;with an incidence of 4% to 9%.<xref ref-type="bibr" rid="article-30468.r7">[7]</xref></p>
        <p>Syphilis, caused by the bacterium&#x000a0;<italic toggle="yes">Treponema pallidum,</italic>&#x000a0;is primarily transmitted sexually but can be transmitted vertically from mother to fetus across&#x000a0;the placenta or through blood transfusions.&#x000a0;In blood transfusion-related cases, the risk of syphilis transmission has significantly decreased due to stringent screening protocols and improved testing methods.</p>
        <p>Numerous methods exist for&#x000a0;evaluating&#x000a0;contamination in platelet products. However,&#x000a0;some methods may not effectively detect contamination when tested immediately after collection,&#x000a0;as sampling typically occurs at least 24 hours after collection.<xref ref-type="bibr" rid="article-30468.r8">[8]</xref></p>
        <p>Other etiologies of TTD may involve viral or parasitic pathogens. Furthermore, emerging infectious agents and novel pathogens pose ongoing challenges to the safety of the blood supply, necessitating continuous surveillance and adaptation of screening protocols.</p>
        <p>
<bold>Viral&#x000a0;Organisms</bold>
</p>
        <p><bold>Hepatitis A:</bold>&#x000a0;HAV is a distinct member of the family Picornaviridae&#x000a0;and is characterized by a&#x000a0;27 to 32 nm spherical particle with cubic symmetry containing a linear 7.5 kb single-stranded RNA (ssRNA) genome.<xref ref-type="bibr" rid="article-30468.r9">[9]</xref>&#x000a0;HAV&#x000a0;exhibits 1 serotype and multiple genotypes. The virus exists in the stool and blood of infected patients and is usually transmitted via the fecal-oral route.<xref ref-type="bibr" rid="article-30468.r10">[10]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>Hepatitis B virus:&#x000a0;</bold>HBV is a member of the hepadnavirus, characterized by&#x000a0;a 3.2 kb double-stranded DNA (dsDNA) genome.<xref ref-type="bibr" rid="article-30468.r11">[11]</xref>&#x000a0;The virus&#x000a0;comprises an outer envelope and an inner core. The outer envelope contains the hepatitis B surface antigen (HBsAg) and a surface protein detectable by blood tests. The inner core of the virus is a protein shell referred to as the hepatitis B core antigen (HBcAg),&#x000a0;housing the hepatitis B virus DNA and enzymes used in viral replication.<xref ref-type="bibr" rid="article-30468.r12">[12]</xref>&#x000a0;HBV transmission occurs through various routes, including sexual activity, breastfeeding, blood products, organ transplantation, and percutaneous exposure.</p>
        <p><bold>Hepatitis C virus:&#x000a0;</bold>HCV is a 60 nm spherical particle, enveloped member of the family Flaviviridae. It contains a 9.4 kb ssRNA genome.<xref ref-type="bibr" rid="article-30468.r13">[13]</xref>&#x000a0;The species of HCV are categorized into 6 genotypes, each with multiple subtypes, based on genetic differences among HCV isolates.<xref ref-type="bibr" rid="article-30468.r14">[14]</xref>&#x000a0;HCV transmission occurs&#x000a0;through blood transfusions, percutaneous exposure, organ transplantation, and, rarely, through sexual activity.</p>
        <p><bold>Human immunodeficiency virus:</bold>&#x000a0;A retrovirus that comprises 2 subtypes, HIV-1 is the most prevalent worldwide and the most common etiological agent of AIDS. HIV-2 is primarily found in West Africa.<xref ref-type="bibr" rid="article-30468.r15">[15]</xref>&#x000a0;HIV transmission occurs via sexual activity, percutaneous exposure, blood transfusions, and during the perinatal period.</p>
        <p><bold>Human T-lymphotropic virus:&#x000a0;</bold>A human retrovirus well-known to cause adult T-cell leukemia, lymphoma, and HTLV-I-associated myelopathy (HAM) or tropical spastic paraparesis.<xref ref-type="bibr" rid="article-30468.r16">[16]</xref><xref ref-type="bibr" rid="article-30468.r17">[17]</xref>&#x000a0;HTLV-I is primarily transmitted by breastfeeding. Spread via blood transfusion, sharing of needles, and sexual intercourse also occur.<xref ref-type="bibr" rid="article-30468.r17">[17]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>West Nile virus:</bold>&#x000a0;An enveloped ssRNA virus within the family Flaviviridae, WNV threatens many transfusion services worldwide.<xref ref-type="bibr" rid="article-30468.r18">[18]</xref>&#x000a0;Transmission among humans exists through mosquito bites, blood transfusion, intrauterine exposure, breastfeeding, and organ transplantation.<xref ref-type="bibr" rid="article-30468.r18">[18]</xref>&#x000a0;</p>
        <p><bold>Cytomegalovirus:&#x000a0;</bold>A member of the family Herpesvirus, CMV has a genome of linear dsDNA and contains a viral capsid of icosahedral symmetry and a viral envelope. Cytomegalovirus can be transmitted in utero, perinatally, and postnatally through close contact, blood transfusions, and organ transplantation.&#x000a0;</p>
        <p><bold>Zika virus:&#x000a0;</bold>A flavivirus; transmission of Zika virus occurs via the bite of an infected mosquito, maternal-fetal transmission, sexual activity, transfusion of blood products, and organ transplantation.&#x000a0;&#x000a0;</p>
        <p><bold>Severe acute respiratory syndrome coronavirus:&#x000a0;</bold>A member of the family Coronaviridae, SARS-CoV-1 is a medium-sized enveloped positive-stranded RNA virus. SARS predominately spreads via droplets and fomites.</p>
        <p><bold>Parvovirus B19:</bold>&#x000a0;A member of the family Parvoviridae, parvovirus B19 is a 5.6 kb, nonenveloped, ssDNA virus. The only known host for parvovirus B19 is humans. Parvovirus B19 transmission occurs through respiratory, vertical, or hematogenous spread.</p>
        <p>
<bold>Parasitic Organisms</bold>
</p>
        <p><bold>Malaria:</bold>&#x000a0;An infectious illness caused by parasites of the&#x000a0;<italic toggle="yes">Plasmodium</italic>&#x000a0;genus, malaria transmission occurs through bites of female<italic toggle="yes">&#x000a0;Anopheles</italic>&#x000a0;mosquitoes. Blood transfusion collected from asymptomatic or infected donors with a low parasite burden may transmit Plasmodium. Erythrocyte concentrate, fresh frozen plasma, cryoprecipitate, and platelet concentrate can all result in transfusion-transmitted malaria.<xref ref-type="bibr" rid="article-30468.r19">[19]</xref>&#x000a0;</p>
        <p><bold><italic toggle="yes">Trypanosoma cruzi:</italic></bold><italic toggle="yes">&#x000a0;</italic>The pathogenic cause of Chagas disease, vector-borne transmission is the most likely transmission mode for this disease. Platelet transfusions pose a higher transmission risk than other blood components.<xref ref-type="bibr" rid="article-30468.r20">[20]</xref>&#x000a0;</p>
        <p><bold>Babesiosis:&#x000a0;</bold>Primarily transmitted through the bite of a tick, this protozoa of the genus <italic toggle="yes">Babesia</italic> can also be transmitted through blood transfusion and solid organ transplantation.&#x000a0;&#x000a0;</p>
        <p>
<bold>Prion Diseases</bold>
</p>
        <p>Prions are abnormal proteins that cause central nervous system neurodegenerative diseases called transmissible spongiform encephalopathies like CJD. Prions exhibit a lengthy asymptomatic dormant period and resist typical sterilization methods. Currently, transfusion has only transmitted variant Creutzfeldt-Jakob disease (vCJD). Nevertheless, a theoretical risk exists that blood product transfusion could transmit other forms of CJD.</p>
      </sec>
      <sec id="article-30468.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Infectious causes currently account for less than 15% of all transfusion-related mortality.<xref ref-type="bibr" rid="article-30468.r21">[21]</xref>&#x000a0;Advancements in screening techniques and blood product processing have significantly reduced the incidence of transfusion-related infections, further enhancing the safety of transfusion medicine.</p>
        <p>
<bold>Bacterial Infection</bold>
</p>
        <p>The risk of contamination with bacterial pathogens is 1 in 5,000 for platelets and 1 in 30,000 for RBCs.<xref ref-type="bibr" rid="article-30468.r22">[22]</xref>&#x000a0;Despite&#x000a0;this&#x000a0;prevalence, bacterial contamination may not&#x000a0;always result in clinical illness in recipients due to insufficient bacterial inocula or blood contamination during testing. Nevertheless, immunocompromised patients remain the most vulnerable population.<xref ref-type="bibr" rid="article-30468.r23">[23]</xref>&#x000a0;</p>
        <p>The World Health Organization estimates that nearly 7.1 million adults between the ages of 15 and 49 acquired syphilis in 2020. The transmission of syphilis via blood products is rare because refrigeration destroys the causal agent,&#x000a0;<italic toggle="yes">T.</italic><italic toggle="yes">&#x000a0;pallidum,&#x000a0;</italic>after 24 to 48 hours<italic toggle="yes">.&#x000a0;</italic></p>
        <p>
<bold>Viral Infection</bold>
</p>
        <p><bold><bold>Human immunodeficiency virus</bold>:</bold>&#x000a0;The estimated number of humans living with HIV and AIDS is 36.7 million worldwide as of 2016. The risk of acquiring HIV infection from a blood transfusion is 1 in 1 to 2 million units in the US, 1 in 8 to 10 million units in Canada, and 1 in 1 to 5 million units in parts of Europe.<xref ref-type="bibr" rid="article-30468.r24">[24]</xref><xref ref-type="bibr" rid="article-30468.r25">[25]</xref>&#x000a0;Risk factors&#x000a0;for acquiring HIV infection&#x000a0;include engaging in unsafe sexual practices, particularly among men who have sex with men,&#x000a0;the use of intravenous drugs, and receiving blood products&#x000a0;contaminated with&#x000a0;the virus.<xref ref-type="bibr" rid="article-30468.r26">[26]</xref><xref ref-type="bibr" rid="article-30468.r27">[27]</xref></p>
        <p><bold>Hepatitis:</bold>&#x000a0;Nearly 240 million individuals worldwide are chronically infected with HBV, leading to over deaths annually from&#x000a0;complications like cirrhosis and hepatocellular carcinoma. Additionally, approximately 150 million individuals&#x000a0;globally have chronic HCV infection,&#x000a0;with nearly 700,000&#x000a0;deaths occurring each year&#x000a0;due to liver disease.<xref ref-type="bibr" rid="article-30468.r13">[13]</xref>&#x000a0;HBV and HBC infections are widespread, with the highest incidence&#x000a0;observed among patients undergoing hemodialysis,&#x000a0;those with HIV infection, and&#x000a0;individuals with coagulation disorders. The risk of acquiring hepatitis B from a blood transfusion is 1 in 1 to 1.5 million. The risk of acquiring hepatitis C is 1 in 2 to 2.6 million.<xref ref-type="bibr" rid="article-30468.r28">[28]</xref><xref ref-type="bibr" rid="article-30468.r29">[29]</xref></p>
        <p><bold>Human T-lymphotropic virus I:</bold>&#x000a0;Approximately 15 million people worldwide&#x000a0;live with chronic&#x000a0;HTLV-I infection. The risk of HTLV-I transmission through a blood transfusion is 1 in 2.7 million.<xref ref-type="bibr" rid="article-30468.r30">[30]</xref></p>
        <p><bold>West Nile virus:</bold> Numerous pathogenic isolates of WNV exist, but the two major lineages, L1 and L2, are responsible for most outbreaks. L1 strains predominantly cause infections in North America, Central America, South America, Africa, and the Middle East, while L2 predominates in sub-Saharan Africa, Madagascar, and Eastern Europe. An independent L2 strain, identified in southern Russia in 2004, led to neuroinvasive West Nile disease outbreaks in Romania starting in 2010. The virus primarily circulates between wild birds and mosquitoes. Approximately 1 in 150 WNV infections result in severe neurologic illness, with older individuals being mainly affected.</p>
        <p><bold>Cytomegalovirus:</bold>&#x000a0;The seroprevalence rates of CMV vary between 40% and 100% worldwide. The presence of CMV antibodies increases with age. The estimated risk of contracting CMV is 0.38% per unit of blood.&#x000a0;</p>
        <p><bold>Zika virus: </bold>Approximately&#x000a0;20%&#x000a0;to 25% of&#x000a0;patients infected with Zika virus&#x000a0;develop symptomatic infection.&#x000a0;Although no confirmed cases of Zika virus transmission via blood transfusion have been reported, there have been confirmed&#x000a0;cases of transmission via platelet transfusion. While 1 study&#x000a0;suggests that women and patients younger than 40 are more likely to develop symptomatic infections, age and sex do not appear to&#x000a0;influence overall infection rates.&#x000a0;</p>
        <p><bold>Severe acute respiratory syndrome coronavirus:&#x000a0;</bold>No cases of SARS-CoV-1 have&#x000a0;been reported since 2004, but the possibility of its reemergence remains. The outbreak in 2003 involved 8096 cases and resulted in 774 deaths,&#x000a0;yielding an overall case-fatality rate of 9% to 12%.&#x000a0;</p>
        <p><bold>Parvovirus B19:&#x000a0;</bold>Parvovirus B19 is&#x000a0;prevalent&#x000a0;worldwide, with infections&#x000a0;peaking in the US in late winter and early summer. Between 50% and 80% of adults in the US&#x000a0;show evidence of previous parvovirus B19 infection. Recipients receiving blood products created from large pools have a higher risk of acquiring parvovirus than recipients who receive blood products from a single donor.</p>
        <p>
<bold>Parasitic Infection</bold>
</p>
        <p><bold>Malaria:</bold>&#x000a0;More than 95% of the world's malaria cases&#x000a0;are concentrated&#x000a0;in the African region.&#x000a0;According to the World Health Organization's 2021 report, there are 247 million malaria cases worldwide.<xref ref-type="bibr" rid="article-30468.r31">[31]</xref>&#x000a0;The risk of acquiring malaria through transfusion varies based on the incidence and prevalence of the disease in a particular area. In the US, the risk of malaria transmission through blood products is less than 1 per 1 million units of blood.&#x000a0;</p>
        <p><bold>Chagas disease:</bold>&#x000a0;A prevailing public health issue in Latin America, Chagas disease affects approximately 10 million individuals globally.<xref ref-type="bibr" rid="article-30468.r31">[31]</xref>&#x000a0;Previously, platelet transfusion carried a 13% risk of Chagas disease. However, since the implementation of mandated screening in the US, no new cases have been reported since 2007.</p>
        <p><bold>Babesiosis:&#x000a0;</bold><italic toggle="yes">Babesia microtia&#x000a0;</italic>is the primary species causing human disease in the US, with the highest concentration in the northeastern and upper Midwest portions. In Europe,&#x000a0;<italic toggle="yes">B divergens&#x000a0;</italic>predominates, while in Asia,&#x000a0;<italic toggle="yes">B venatorum, B microti, B crassa-like organisms,&#x000a0;</italic>and&#x000a0;<italic toggle="yes">B motasi-like organisms&#x000a0;</italic>are responsible for disease. Transfusion-transmitted babesiosis most frequently occurs between June and November. To date, more than 250 transfusion-transmitted cases of babesiosis have been reported. Risk factors for developing babesiosis include immunosuppression, travel to endemic areas, and having a blood transfusion within the previous 6 months.<bold>&#x000a0;</bold></p>
      </sec>
      <sec id="article-30468.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Recognizing TTBI can be challenging due to similarities with other transfusion reactions or underlying medical conditions. Patients may exhibit symptoms during or within 72 hours of the transfusion, influenced by the inoculum's size and virulence. The clinical presentation of TTBI varies widely, and clinicians must uphold a heightened clinical suspicion. Affected individuals may be asymptomatic or experience septic shock. Indications of a septic transfusion reaction include common clinical signs:</p>
        <list list-type="bullet">
          <list-item>
            <p>Temperature &#x0003e;102.2 &#x000b0;F (39 &#x000b0;C)</p>
          </list-item>
          <list-item>
            <p>A temperature increase of &#x0003e;3.6 &#x000b0;F (2 &#x000b0;C) within a few hours following transfusion</p>
          </list-item>
          <list-item>
            <p>Rigors</p>
          </list-item>
          <list-item>
            <p>Heart rate &#x0003e;120 bpm</p>
          </list-item>
          <list-item>
            <p>A heart rate increase of &#x02265;40 bpm within a few hours following transfusion</p>
          </list-item>
          <list-item>
            <p>Rise or fall in systolic blood pressure &#x0003e;30 mm Hg</p>
          </list-item>
        </list>
        <p>Nausea, vomiting, abdominal pain, back pain, and hypothermia are additional potential symptoms.</p>
        <p>
<bold>Syphilis</bold>
</p>
        <p>Syphilis, when sexually transmitted, manifests as a painless ulcer around the genital, oral, or anal areas. If&#x000a0;left&#x000a0;untreated, the infection progresses to the secondary stage within 3 to 6 weeks, characterized by a rash on the palms and soles, along with symptoms like lymphadenopathy, fever, weight loss, sore throat, patchy hair loss, headache, and muscle aches. The latent stage follows, with no apparent signs or symptoms. Tertiary syphilis, occurring 10 to 30 years post-infection, can involve the heart, blood vessels, brain, nervous system, eyes, and ears, though most individuals do not develop this stage.</p>
        <p>
<bold>Viral Infection</bold>
</p>
        <p>
<bold>Hepatitis B&#x000a0;</bold>
</p>
        <p>Subclinical disease occurs in 70% of patients with an acute HBV infection, while the remaining 30% will progress to icteric hepatitis. Fulminant hepatic failure is rare, developing in 0.1% to 0.5% of patients. The incubation period for HBV is typically 1 to 4 months. Alongside icteric hepatitis, individuals may experience additional symptoms such as fatigue, myalgias, nausea, vomiting, jaundice, diarrhea, right upper quadrant pain, dark urine, and clay-colored stools.</p>
        <p>
<bold>Hepatitis C</bold>
</p>
        <p>The majority of patients experiencing an acute HCV infection remain asymptomatic. When symptomatic, affected patients manifest symptoms between 2&#x000a0;and 26 weeks after exposure. The hallmark symptoms are fatigue, low-grade fever, chills, loss of appetite, pruritus, myalgias, mood disturbances, joint pain, dyspepsia, confusion, clay-colored stools, and dark urine.</p>
        <p>
<bold>
<bold>Human immunodeficiency virus</bold>
</bold>
</p>
        <p>Primary HIV infection, marked by various symptoms, typically emerges 4 to 10 weeks following exposure.<xref ref-type="bibr" rid="article-30468.r26">[26]</xref>&#x000a0;Shallow, sharply demarcated ulcerations with white bases surrounded by a thin area of erythema located on the oral mucosa, anus, penis, or esophagus are characteristic findings associated with an acute HIV infection. The hallmark skin rash consists of 5 to 10-mm red macules most commonly located on the upper chest, collar area, and face. The remaining symptoms may include fever, joint pain, headache, sore throat, fatigue, diarrhea, weight loss, and lymphadenopathy affecting the axillary, cervical, and occipital nodes. The progression of chronic HIV disease can lead to AIDS, which carries a high mortality rate attributed to opportunistic infections and malignant tumors.<xref ref-type="bibr" rid="article-30468.r26">[26]</xref></p>
        <p>
<bold>Human T lymphotropic virus I&#x000a0;</bold>
</p>
        <p>The majority of individuals with HTLV-I will not exhibit symptoms, leading to disease manifestation in approximately 5% of infected patients.<xref ref-type="bibr" rid="article-30468.r32">[32]</xref><xref ref-type="bibr" rid="article-30468.r33">[33]</xref>&#x000a0;HTLV-I infection is known to cause adult T-cell leukemia-lymphoma and HTLV-I-associated myelopathy (HAM) or tropical spastic paraparesis.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Adult T-cell leukemia-lymphoma:</bold>&#x000a0;Adult T-cell leukemia-lymphoma, a lymphoproliferative disorder, manifests in various forms listed in decreasing prevalence: acute, lymphomatous, chronic, and smoldering. The acute form is characterized by skin nodules, ulcers, a generalized papular rash, lytic bone lesions, hypercalcemia, and pulmonary infiltrates. The lymphomatous form presents lymphadenopathy, hepatosplenomegaly, and skin lesions.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>HTLV-I-associated myelopathy or tropical spastic paraparesis:&#x000a0;</bold>Symptoms of HAM can appear anytime between 4 months and 30 years after the initial infection.<bold>&#x000a0;</bold>Affected patients may present with the following symptoms and physical examination findings:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Gait difficulties</p>
              </list-item>
              <list-item>
                <p>Low back pain</p>
              </list-item>
              <list-item>
                <p>Unexplained falls</p>
              </list-item>
              <list-item>
                <p>Constipation</p>
              </list-item>
              <list-item>
                <p>Urinary urgency and incontinence</p>
              </list-item>
              <list-item>
                <p>Numbness or pain in the lower extremities</p>
              </list-item>
              <list-item>
                <p>Patellar hyperreflexia</p>
              </list-item>
              <list-item>
                <p>Bilateral ankle clonus</p>
              </list-item>
              <list-item>
                <p>Spasticity in both lower extremities</p>
              </list-item>
              <list-item>
                <p>Loss of vibratory sense&#x000a0;<xref ref-type="bibr" rid="article-30468.r32">[32]</xref><xref ref-type="bibr" rid="article-30468.r33">[33]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>West Nile virus</bold>
</p>
        <p>Between 2 and 14 days after infection, 20% to 40% of patients with WNV experience symptomatic presentation. The infection may manifest with various signs and symptoms, including fever, headache, body aches, skin rash, swollen lymph nodes, stiff neck, sleepiness, coma, seizures, and eye pain. In addition, affected patients may develop neuroinvasive diseases like meningitis, encephalitis, flaccid paralysis, or a combination of these conditions. Following the acute phase, many patients experience residual symptoms such as fatigue, memory impairment, weakness, headache, and difficulties with balance.</p>
        <p>
<bold>Cytomegalovirus</bold>
</p>
        <p>During an acute infection, many patients may remain asymptomatic. Congenital CMV infections have the potential to cause complications such as sensorineural hearing loss, hepatosplenomegaly, microcephaly, petechiae, seizures, and intracranial calcification. Premature infants and those with compromised immune systems are particularly susceptible to developing complications like myocarditis, retinitis, encephalitis, or encephalopathy. If symptoms manifest in immunocompetent patients, they might experience prolonged fevers and lethargy, resembling a mononucleosis-type illness associated with the Epstein-Barr virus (EBV). Like EBV, CMV enters a latent phase after resolving the acute infection. Notably, patients with a CMV-related illness are less likely to exhibit pharyngitis, splenomegaly, and lymphadenopathy encountered with EBV.</p>
        <p>
<bold>Zika virus</bold>
</p>
        <p>The Zika virus has an incubation period ranging from 2 to 14 days. Symptoms include the sudden onset of low-grade fever, a pruritic rash affecting the face, trunk, extremities, palms, and soles, arthralgia predominantly in the small joints of the hands and feet, and nonpurulent conjunctivitis. Myalgia, retro-orbital pain, and asthenia are also possible symptoms. Certain patients may report recurring symptoms without a new acute infection.</p>
        <p>
<bold>Severe acute respiratory syndrome coronavirus:&#x000a0;</bold>
</p>
        <p>SARS-CoV-1 is a unique respiratory virus in that the prodrome lasts 3 to 7 days. Patients experience fever, myalgias, and malaise but no respiratory symptoms during the prodrome. A dry, nonproductive cough begins at the end of the prodrome. Affected patients may progress to respiratory failure. The most common symptoms associated with SARS are fever, cough, chills or rigors, myalgias, dyspnea, and headache.</p>
        <p>
<bold>Parvovirus B19:</bold>
</p>
        <p>Nearly 25% of infected patients will remain completely asymptomatic, though 50% will experience malaise, muscle pain, and fever that lasts approximately 3 days. The remaining 25% present will develop either the rash of erythema infectiosum or arthralgias. Children most often develop erythema infectiosum, and adults frequently develop arthralgias. Due to the destruction of erythrocyte progenitor cells, a decrease or absence of reticulocyte count is the hallmark laboratory finding associated with parvovirus B19 infection.</p>
        <p>
<bold>Parasitic&#x000a0;Infection</bold>
</p>
        <p>
<bold>Malaria</bold>
</p>
        <p>Symptoms of malaria typically develop between 12 and 35 days after exposure. Some may become symptomatic as early as 7 days after exposure. Classically, infected patients present with paroxysms of high fevers, profuse sweating, rigors, and headache. Febrile seizures may occur in children. Gastrointestinal symptoms may include nausea, vomiting, abdominal pain, diarrhea, and bloody stools. Lethargy and pallor due to anemia and splenomegaly are classic physical examination findings.&#x000a0;</p>
        <p>
<bold>Chagas disease</bold>
</p>
        <p>The incubation period is generally 1 to 2 weeks. Infected patients develop 2 phases, acute and chronic.<xref ref-type="bibr" rid="article-30468.r34">[34]</xref>&#x000a0;The acute phase lasts approximately 8 to 12 weeks. Most patients are asymptomatic or have mild symptoms like malaise, fever, and anorexia. Less common findings during the acute phase are a chagoma, myocarditis, pericardial effusion, or meningoencephalitis.</p>
        <p>Patients who do not receive proper treatment enter the chronic phase that lasts the remainder of their life. Most patients develop the indeterminate or asymptomatic form during the chronic phase's first 10 to 30 years.&#x000a0;However, 20% to 40% will develop the determinant form involving the cardiac and gastrointestinal systems. Potential symptoms associated with the chronic phase of the Chagas disease are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Arrhythmias&#x000a0;</p>
          </list-item>
          <list-item>
            <p>ECG changes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Syncope&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Palpitations&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic abdominal pain&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic constipation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dilated colon&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Shortness of breath&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Emphysema&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Stroke&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sudden death</p>
          </list-item>
        </list>
        <p>
<bold>Babesiosis</bold>
</p>
        <p>The incubation period after a tick bite is 1 to 4 weeks. Following the transfusion of blood products, the incubation period is 3 to 7 weeks but may be as long as 6 months. Many patients remain asymptomatic. Fever, fatigue, malaise, myalgias, and dry cough are common presenting symptoms. Immunocompromised patients are at risk for progressing to severe disease manifesting as acute respiratory distress syndrome, congestive heart failure, renal failure, disseminated intravascular coagulation, shock, splenic rupture, and coma. Anemia, thrombocytopenia, elevated lactate dehydrogenase, elevated creatinine, and elevated liver enzymes are potential lab abnormalities encountered in patients with babesiosis.&#x000a0;</p>
      </sec>
      <sec id="article-30468.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Thorough evaluation of potential donors and rigorous testing of blood products are essential to safeguard the blood supply's integrity. Donation centers administer a comprehensive donor questionnaire to assess any factors that could compromise the safety of donated blood. This questionnaire covers various aspects, including the history of intravenous drug use, recent travel, current illness or antibiotic usage, HIV or hepatitis infection, as well as vaccine history. In addition to donor screening, blood products undergo screening tests for:</p>
        <list list-type="bullet">
          <list-item>
            <p>HBV and HCV</p>
          </list-item>
          <list-item>
            <p>HIV-1 and HIV-2</p>
          </list-item>
          <list-item>
            <p>HTLV-I and HTLV-II</p>
          </list-item>
          <list-item>
            <p>Zika virus</p>
          </list-item>
          <list-item>
            <p>West Nile virus</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">T&#x000a0;pallidum</italic>
</p>
          </list-item>
          <list-item>
            <p>
<italic toggle="yes">T&#x000a0;cruzi</italic>
</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Babesia</italic>&#x000a0;in states where testing is required based on FDA guidance&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Bacterial Testing</bold>
</p>
        <p>Most donation centers perform bacterial cultures on platelet products&#x000a0;obtained from 1 donor. The center releases the platelets if the cultures reveal no growth after 24 to 36 hours. Platelets collected from multiple donors may undergo screening for bacterial contamination by hospital transfusion services.&#x000a0;</p>
        <p>Screening for syphilis utilizes both treponemal and nontreponemal assays. Nontreponemal tests like the rapid plasma reagin (RPR) test and the venereal disease research laboratory (VDRL) test detect antibodies directed against an antigen called cardiolipin present in patients with active syphilis. The RPR and VDRL can remain positive for 1 to 2 years after treatment in previously infected patients.&#x000a0;</p>
        <p>Available treponemal assays are enzyme immunoassays (EIA), fluorescent treponemal antibody absorbed assays (FTA-ABS),&#x000a0;<italic toggle="yes">Treponema pallidum</italic>&#x000a0;microhemagglutination assays (MHA-TPA), and&#x000a0;<italic toggle="yes">Treponema pallidum</italic>&#x000a0;particle agglutination assays (TP-PA). These assays test for antibodies to antigens that are specific to treponemes. Treponemal assays will remain positive throughout a patient's life regardless of treatment.&#x000a0;</p>
        <p>
<bold>Viral Testing</bold>
</p>
        <p>Donor blood products in most developed countries undergo screening for HBV through HBsAg tests. To address potential challenges in detecting low levels of HBsAg in patients who are chronic carriers of HBV, donation centers may also employ assays to identify anti-HBc. Anti-HBc antibodies emerge early in the infection and remain positive. HBV nucleic acid testing (NAT) becomes crucial for detecting HBV DNA in individuals with chronic infection, undetectable levels of HBsAg, and indeterminate levels of anti-HBc.<xref ref-type="bibr" rid="article-30468.r11">[11]</xref>&#x000a0;</p>
        <p>HBsAg establishes a detection window spanning 3 to 40 days, whereas NAT reduces this window to 3 to 4 weeks. Assays targeting anti-HBc may yield positive results within 1 week of infection but are associated with a false positive rate of 1%.</p>
        <p>Donation centers screen for HCV using tests for anti-HCV antibodies and NAT detection of HCV RNA. In the US, the standard of care for detecting HCV infection involves mini-pool NAT (MP NAT). This method tests small aliquots from donations of 4 to 16 donors as a single sample.<xref ref-type="bibr" rid="article-30468.r35">[35]</xref>&#x000a0;The current method's window period is 1 to 2 weeks. MP NAT also detects HIV RNA and has replaced p24 antigen testing of donor blood. The window period for HIV using MP NAT is approximately 11 days.</p>
        <p>NAT is the screening method of choice for WNV and Zika virus. Donation centers utilize individual NAT testing for WNV instead of pooled testing because of the high risk of infection from patients with low-level viremia.&#x000a0;Antibody detection assays currently detect CMV, HTLV-I, and HTLV-II.<xref ref-type="bibr" rid="article-30468.r36">[36]</xref>&#x000a0;</p>
        <p>
<bold>Parasite Testing</bold>
</p>
        <p>In Brazilian blood banks, screening for&#x000a0;<italic toggle="yes">P</italic><italic toggle="yes">&#x000a0;falciparum</italic>&#x000a0;relies on examining blood-thick smears. However, a study suggests that employing molecular biology techniques could enhance the efficiency of malaria detection among blood donors. The molecular diagnostic method, utilizing real-time PCR based on mitochondrial DNA (mt-qPCR), has been refined to detect&#x000a0;<italic toggle="yes">P falciparum</italic>,&#x000a0;<italic toggle="yes">P vivax</italic>, and&#x000a0;<italic toggle="yes">P malariae</italic>. The mt-qPCR test demonstrates high analytic sensitivity, proving efficient and effective in identifying potentially infected donors. Incorporation of mt-qPCR testing into the routine screening of asymptomatic carriers could help prevent transfusion-transmitted malaria in blood banks.<xref ref-type="bibr" rid="article-30468.r19">[19]</xref>&#x000a0;&#x000a0;</p>
        <p>The prevalence of inconclusive serology in blood banks and the absence of a universally accepted gold standard test for Chagas disease prompted an investigation into the effectiveness of the blood culture and various commercial tests, including enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence, and hemagglutination assay. These methods proved valuable in detecting anti-<italic toggle="yes">Trypanosoma cruzi</italic>&#x000a0;antibodies. When employed collectively, they exhibited a 100% probability of accurately predicting the absence of infection.<xref ref-type="bibr" rid="article-30468.r37">[37]</xref>&#x000a0;The US uses ELISA-based testing, and endemic countries use serologic testing and deferral of positive donors.</p>
      </sec>
      <sec id="article-30468.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Donation centers and hospitals are responsible for collecting blood products using proper sterile techniques, participating in lookback programs, implementing suitable pathogen inactivation methods, and deferring donors who may pose a potential risk to the blood supply's safety. Additionally, regular training and education of staff regarding blood safety protocols are crucial for maintaining the integrity of the blood supply.</p>
        <p>
<bold>Bacterial Contamination</bold>
</p>
        <p>Donors must be healthy, without active infection or antibiotic usage. Phlebotomy procedures should&#x000a0;include timed cleansing with chlorhexidine to prevent skin flora transfer. To&#x000a0;minimize the risk of introducing skin flora, the initial 15 to 30 mL of blood undergoes testing for blood bank and infectious diseases.<xref ref-type="bibr" rid="article-30468.r4">[4]</xref>&#x000a0;</p>
        <p>Distinguishing&#x000a0;between septic and other transfusion reactions can be challenging. If a patient develops symptoms, clinicians should stop the transfusion and send the blood product for a Gram stain and culture.&#x000a0;Additionally, they should repeat the type and cross-match and collect blood for the patient's Coombs test and bacterial culture.&#x000a0;Initiation of&#x000a0;empiric antibiotics and any other necessary treatments like fluid resuscitation should be promptly undertaken.</p>
        <p>
<bold>Lookback Programs</bold>
</p>
        <p>Lookback programs are designed to alert recipients who have received blood products from a donor who initially tested negative for an infectious agent but has since tested positive. The primary goal of these programs is to halt the potential spread of the infectious agent and offer affected recipients an opportunity to seek medical evaluation and care.</p>
        <p>For instance, confirmatory testing is conducted at the donation center if a donor's blood tests positive for HCV. If confirmed positive, the center discards the blood product and informs the hospital where the donor previously donated blood. The hospital is responsible for identifying any patients who may have received blood from that donor in the past. Subsequently, the donation center notifies the recipient's current healthcare provider or the clinician who initially requested the blood product. It is then the clinician's responsibility to inform the patient and arrange for the recommended testing.</p>
        <p>
<bold>Pathogen Inactivation</bold>
</p>
        <p>Pathogen inactivation serves to inactivate most clinically relevant viruses, bacteria, and protozoa, which helps to eliminate the residual risk of infection during the window period when donor screening tests cannot detect transfusion-relevant pathogens.<xref ref-type="bibr" rid="article-30468.r38">[38]</xref>&#x000a0;Additionally, pathogen inactivation techniques enhance the safety and efficacy of blood transfusion practices.</p>
        <p>
<bold>Solvent-Detergent method</bold>
</p>
        <p>This method disrupts membranes of lipid-enveloped viruses like HIV, HTLV, EBV, HBV, and HCV. The solvent-detergent method is not effective against HAV, parvovirus, or prions. In the US, clinicians&#x000a0;tend to avoid&#x000a0;this method because it causes the loss of protein S, antitrypsin, and antiplasmin during the removal of the solvent-detergent, leading to some fatalities.&#x000a0;Nevertheless, certain regions of Europe still utilize this technique.<xref ref-type="bibr" rid="article-30468.r39">[39]</xref></p>
        <p>
<bold>Methylene blue</bold>
</p>
        <p>Methylene blue, used in Europe to eliminate viruses, attaches to cellular elements and, when exposed to light, becomes active and destroys the wall where it has attached. Methylene blue is not effective against intracellular organisms or prions.<xref ref-type="bibr" rid="article-30468.r39">[39]</xref></p>
        <p>
<bold>Synthetic Psoralen</bold>
</p>
        <p>Synthetic psoralen stops the multiplication of nearly all currently screened for pathogens. After exposure to ultraviolet (UV) light, synthetic psoralen forms cross-links in the nucleic acid chains. Synthetic psoralen does decrease platelet activity, requiring more frequent platelet transfusions.&#x000a0;<xref ref-type="bibr" rid="article-30468.r39">[39]</xref></p>
        <p>
<bold>Riboflavin</bold>
</p>
        <p>In addition to UV light, riboflavin can inactivate pathogens in platelets and plasma without affecting the coagulant and anticoagulant properties. Because riboflavin is a natural product, it does not require removal at the end of the process.<xref ref-type="bibr" rid="article-30468.r39">[39]</xref>&#x000a0;</p>
        <p>
<bold>Leukodepletion</bold>
</p>
        <p>Given the high prevalence of CMV-positive donors in the general population, CMV-negative blood products may be challenging to find. CMV resides within the white blood cells, and donation centers filter leukocytes from the&#x000a0;RBCs&#x000a0;to prevent CMV transmission to immunocompromised patients and infants. The data is unclear if filtering leukocytes from&#x000a0;RBCs is as effective as transfusing CMV-negative blood products.<xref ref-type="bibr" rid="article-30468.r39">[39]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Heat pasteurization</bold>
</p>
        <p>Heat pasteurization&#x000a0;entails treating therapeutic plasma proteins such as human albumin, coagulation factors, immunoglobulins, and enzyme inhibitors at 60 &#x000b0;C for 10 hours to deactivate blood-borne viruses. This method effectively reduces the risk of TTDs while preserving the therapeutic properties of the plasma proteins.</p>
        <p>
<bold>Nanofiltration</bold>
</p>
        <p>Nanofiltration involves filtering protein solutions through membranes featuring nanometric-sized pores. These membranes serve to retain a variety of viruses.</p>
        <p>
<bold>Deferral of Donation</bold>
</p>
        <p>"Donation centers permanently defer donors with a history of HIV, AIDS, hepatitis, Creutzfeldt-Jakob Disease (CJD), a dura mater transplant, Chagas Disease, or leishmaniasis. For individuals receiving medication to prevent HIV infection, the deferral period is 2 years after the last injection. Donors detained or incarcerated in a facility for more than 72 hours must wait 12 months before donating."</p>
        <p>The waiting period&#x000a0;for donation is&#x000a0;3 months after receiving a blood transfusion from another donor,&#x000a0;engaging in sexual contact with a person who has hepatitis,&#x000a0;experiencing a nonsterile needle stick, exposure to someone else's blood, last&#x000a0;intravenous drug use or the last dose of any oral medications taken to prevent HIV infection. Donors with a history of malaria or residents of endemic countries may not donate for 3 years. Travelers to endemic areas may not donate for 1 year from return.<xref ref-type="bibr" rid="article-30468.r40">[40]</xref></p>
      </sec>
      <sec id="article-30468.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The primary challenge with TTD is distinguishing TTBI from other transfusion reactions. Several other transfusion reactions begin with fever and chills. The following list includes the differential diagnoses of TTD:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Febrile nonhemolytic transfusion reaction: Noted fever and chills without additional systemic symptoms.&#x000a0;Because the development of additional systemic symptoms is unknown at the onset of the fever, febrile nonhemolytic transfusion reaction is a diagnosis of exclusion.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute hemolytic transfusion reaction: Involves the acute intravascular hemolysis of transfused red blood cells, often due to ABO incompatibility. The classic symptoms are fever, chills, flank pain, and oozing from intravenous sites.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transfusion-related acute lung injury: Presents with Fever, chills, and respiratory distress due to anti-HLA or anti-neutrophil antibodies from the donor blood activating the recipient's neutrophils.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypotensive transfusion reactions: Present as a decrease in systolic blood pressure of 30 mm Hg or more without any other identifiable cause. The patient's blood pressure returns to normal on discontinuation of the transfusion.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Preexisting infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transfusion-associated graft versus host disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30468.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of TTD depends on the specific pathogen, the availability and quality of healthcare in the recipient's country, and the recipient's immune status. Deaths due to TTBI are more likely with gram-negative organisms. Recent data reveals 2 to 3 deaths per year in the US due to TTBI.</p>
        <p>Between 12% and&#x000a0;20% of patients with chronic HBV&#x000a0;progress to cirrhosis.&#x000a0;Among those who develop cirrhosis, approximately 20%&#x000a0;experience hepatic decompensation, and 6% to 15% develop hepatocellular carcinoma. Patients with compensated cirrhosis have a survival rate of 85% at 5 years. Those with decompensated cirrhosis have a 14% to 35% survival at 5 years.<xref ref-type="bibr" rid="article-30468.r41">[41]</xref></p>
        <p>Between 50%&#x000a0;to 85% of patients infected with HCV&#x000a0;develop&#x000a0;chronic&#x000a0;infection.&#x000a0;Over the following 20 to 30 years, 5% &#x000a0;to 30%&#x000a0;progress to cirrhosis. The estimated annual death&#x000a0;toll from HCV in the US is 8000 to 13,000.</p>
        <p>Without antiretroviral therapy, the average life expectancy after HIV infection is 12 to 18 months. Initiation of antiretroviral therapy can lead to a near-normal lifespan.</p>
        <p>Serious adverse outcomes associated with WNV occur primarily in patients who develop neuroinvasive disease. The estimated mortality rates are 2% in patients with meningitis, 14% in patients with encephalitis, and 13% in those with acute flaccid paralysis.<xref ref-type="bibr" rid="article-30468.r42">[42]</xref>&#x000a0;Malaria infection carries a&#x000a0;favorable prognosis if appropriately treated. Nonetheless, over 600,000 people die from malaria each year, with most&#x000a0;being children under the age of 5 in Africa.&#x000a0;</p>
        <p>Survival rates for adult T-cell leukemia-lymphoma vary based on the form. The acute form has a median survival rate of approximately 6 months. On the other hand, the chronic form has a median survival of 2 years, and the smoldering form extends up to 5 years.</p>
        <p>Mortality associated with chronic Chagas disease is almost exclusively related to cardiovascular involvement. The annual all-cause mortality rate is 7.9%, and the yearly cardiovascular death rate is 6.3%. &#x000a0;</p>
      </sec>
      <sec id="article-30468.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of TTD are specific to the transmitted pathogen. These are broken down as follows:</p>
        <p>
<bold>West Nile Virus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chorioretinitis</p>
          </list-item>
          <list-item>
            <p>Retinal hemorrhages</p>
          </list-item>
          <list-item>
            <p>Vitreitis</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
          <list-item>
            <p>Fatal hemorrhagic fever with multiple organ failure and palpable purpura&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatitis and pancreatitis</p>
          </list-item>
          <list-item>
            <p>Central diabetes insipidus</p>
          </list-item>
          <list-item>
            <p>Myocarditis</p>
          </list-item>
          <list-item>
            <p>Myositis</p>
          </list-item>
          <list-item>
            <p>Orchitis</p>
          </list-item>
          <list-item>
            <p>Brachial plexopathy</p>
          </list-item>
          <list-item>
            <p>Demyelinating neuropathy</p>
          </list-item>
          <list-item>
            <p>Motor axonopathy</p>
          </list-item>
          <list-item>
            <p>Axonal polyneuropathy</p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis</p>
          </list-item>
          <list-item>
            <p>Acute transverse myelitis</p>
          </list-item>
          <list-item>
            <p>Symptoms similar to Guillain-Barr&#x000e9; syndrome&#x000a0;<xref ref-type="bibr" rid="article-30468.r43">[43]</xref><xref ref-type="bibr" rid="article-30468.r44">[44]</xref><xref ref-type="bibr" rid="article-30468.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>
<bold>HIV&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Opportunistic infections&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Malignancy</p>
          </list-item>
          <list-item>
            <p>Progression to AIDS</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
        <p>
<bold>Hepatitis B and C</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic hepatitis&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Liver failure&#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cirrhosis&#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatocellular carcinoma</p>
          </list-item>
          <list-item>
            <p>Variceal hemorrhage</p>
          </list-item>
          <list-item>
            <p>Encephalopathy</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
        <p>
<bold>Cytomegalovirus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Congenital CMV</p>
          </list-item>
          <list-item>
            <p>Rejection of transplanted organs</p>
          </list-item>
          <list-item>
            <p>Enteritis</p>
          </list-item>
          <list-item>
            <p>Colitis</p>
          </list-item>
          <list-item>
            <p>Hepatitis</p>
          </list-item>
          <list-item>
            <p>Nephritis</p>
          </list-item>
          <list-item>
            <p>Pneumonitis</p>
          </list-item>
          <list-item>
            <p>Meningitis</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
          <list-item>
            <p>Retinitis</p>
          </list-item>
        </list>
        <p>
<bold>Syphilis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aortitis</p>
          </list-item>
          <list-item>
            <p>Gummatous disease</p>
          </list-item>
          <list-item>
            <p>General paresis</p>
          </list-item>
          <list-item>
            <p>Tabes dorsalis</p>
          </list-item>
          <list-item>
            <p>Meningitis</p>
          </list-item>
        </list>
        <p>
<bold>Zika Virus</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Guillain-Barr&#x000e9; syndrome</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
          <list-item>
            <p>Transverse myelitis</p>
          </list-item>
          <list-item>
            <p>Encephalomyelitis</p>
          </list-item>
          <list-item>
            <p>Meningoencephalitis</p>
          </list-item>
          <list-item>
            <p>Chronic inflammatory demyelinating polyneuropathy</p>
          </list-item>
          <list-item>
            <p>Brain ischemia</p>
          </list-item>
          <list-item>
            <p>Neuropsychiatric and cognitive symptoms&#x000a0;<xref ref-type="bibr" rid="article-30468.r46">[46]</xref><xref ref-type="bibr" rid="article-30468.r47">[47]</xref><xref ref-type="bibr" rid="article-30468.r48">[48]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Chagas disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Muscle atrophy</p>
          </list-item>
          <list-item>
            <p>Heart failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Megaesophagus</p>
          </list-item>
          <list-item>
            <p>Megacolon</p>
          </list-item>
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
          <list-item>
            <p>Thromboembolism</p>
          </list-item>
          <list-item>
            <p>Left ventricular wall motion abnormalities</p>
          </list-item>
          <list-item>
            <p>Aspiration</p>
          </list-item>
          <list-item>
            <p>Esophageal fistulas</p>
          </list-item>
          <list-item>
            <p>Esophageal ulcerations</p>
          </list-item>
          <list-item>
            <p>Esophageal perforation</p>
          </list-item>
          <list-item>
            <p>Esophageal bleeding</p>
          </list-item>
          <list-item>
            <p>Hypertrophy of the salivary glands&#x000a0;<xref ref-type="bibr" rid="article-30468.r49">[49]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Malaria</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute respiratory distress syndrome</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Severe anemia</p>
          </list-item>
          <list-item>
            <p>Coagulopathies</p>
          </list-item>
          <list-item>
            <p>Hypoglycemia</p>
          </list-item>
          <list-item>
            <p>Pulmonary edema&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Multiple organ failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Death&#x000a0;<xref ref-type="bibr" rid="article-30468.r50">[50]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Babesiosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute respiratory distress syndrome</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Severe anemia</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Splenic rupture</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
          <list-item>
            <p>Disseminated intravascular coagulation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30468.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>While the US blood supply is currently regarded as highly safe, there remains a potential risk of transmitting blood-borne pathogens during transfusion.&#x000a0;TTDs&#x000a0;can be caused by various organisms, including bacteria, viruses, prions, and parasites. Rigorous measures, such as standard donor screening questionnaires and laboratory tests, are implemented to minimize this risk. Furthermore, using Pathogen Reduction Technology following blood collection provides additional protection against transfusion-transmitted diseases.&#x000a0;</p>
        <p>Parasitic infections transmitted through transfusion are rare but include diseases such as babesiosis, Chagas Disease, leishmaniasis, and malaria. Donation centers question donors about recent travel to assess the risk of transmitting specific infections.&#x000a0;Viral diseases, including HAV, HBV, HCV, HIV, HTLV, WNV, and Zika Virus, can be transmitted through transfusion. However, the risk of transfusion-transmitted viral diseases is extremely low due to rigorous blood supply testing.&#x000a0;Prion diseases, such as vCJD, are rare neurodegenerative disorders also transmitted by blood transfusion. The risk of acquiring vCJD from transfusion is uncertain, and preventative measures are in place to monitor and mitigate potential risks.</p>
        <p>Patients should be informed about the risks associated with blood transfusion, participate in screening processes, and adhere to guidelines provided by healthcare professionals. Blood donors are subject to strict eligibility criteria and deferral periods to prevent potential transmission of infectious agents.&#x000a0;A&#x000a0;complete list of donor eligibility criteria is available on the Red Cross' website at&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.redcrossblood.org/donate-blood/how-to-donate/eligibility-requirements/eligibility-criteria-alphabetical.html">https://www.redcrossblood.org/donate-blood/how-to-donate/eligibility-requirements/eligibility-criteria-alphabetical.html</ext-link>.&#x000a0;</p>
      </sec>
      <sec id="article-30468.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>&#x000a0;Key facts to keep in mind about TTDs are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Transfusion-transmitted leishmaniasis is a concern in endemic regions. Donors should be tested for leishmaniasis using an immunofluorescent antibody, PCR, ELISA, and rapid test. Blood banks should be aware of the threat that imposes leishmania-contaminated blood and should routinely include a test to diagnose this infection.<xref ref-type="bibr" rid="article-30468.r51">[51]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Anaplasma phagocytophilum</italic>&#x000a0;and&#x000a0;<italic toggle="yes">Ehrlichia&#x000a0;</italic>bacteria, resulting in human granulocytic anaplasmosis (HGA) and Ehrlichiosis, respectively, are tick-borne illnesses and present with fever, chills, myalgias, and headache symptoms. Patients with HGA will have polymorphonuclear leukocytes containing morulae in the peripheral smear. Samples from the recipient may test positive by PCR for&#x000a0;<italic toggle="yes">Anaplasma phagocytophilum</italic>.<xref ref-type="bibr" rid="article-30468.r52">[52]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Zika virus exposure during pregnancy can cause congenital microcephaly. Pregnant women should avoid travel to areas of Zika transmission below 6500 ft.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Transfusion of blood products may also transmit yellow fever and dengue fever. Mosquitos transmit both infections. Nearly 400 million people a year become infected with dengue fever annually in the tropics and subtropics of Africa and South America. Affected patients may experience mild illness or progress to severe liver disease with bleeding and jaundice. A vaccine for yellow fever exists.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chikungunya virus transmission may also occur. Chikungunya spreads typically via mosquito bites throughout Africa, Asia, Europe, the Indian and Pacific Oceans, and the Caribbean. Typical symptoms are fever and joint pain.</p>
          </list-item>
          <list-item>
            <p>Prompt diagnosis and management are essential if a TTD is suspected, which may involve discontinuing the transfusion, performing relevant diagnostic tests, and providing appropriate supportive care.&#x000a0;</p>
            <p>
<bold>&#x000a0;</bold>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30468.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Blood transfusions, crucial in medical interventions, can potentially transmit various blood-borne pathogens. Almost 5 million Americans undergo blood transfusions yearly for various medical requirements. Despite the minimal risk, TTDs persist due to donations made during the window period and the potential contamination of blood products.</p>
        <p>Bacterial infections, particularly in platelet transfusions, pose a higher risk than viral infections. Common viral organisms transmitted include HIV, HCV, HBV, WNV, CMV, and others. Ongoing advancements in screening, donor vigilance, and pathogen inactivation enhance blood supply safety. Rigorous donor evaluation and comprehensive testing protocols, encompassing bacterial, viral, and parasitic screenings, help ensure the safety of the blood supply. Vigilance programs, lookback initiatives, and pathogen inactivation techniques further contribute to comprehensive transfusion safety.</p>
        <p>Healthcare professionals must discuss skills, strategy, interprofessional communication, and care coordination by physicians, advanced practitioners, nurses, pharmacists, and other health professionals to enhance patient-centered care, outcomes, patient safety, and team performance related to TTDs</p>
      </sec>
      <sec id="article-30468.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30468&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30468">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/transfusion-transmitted-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30468">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30468/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30468">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30468.s15">
        <title>References</title>
        <ref id="article-30468.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seifried</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Klueter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weidmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Staudenmaier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schrezenmeier</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Henschler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>How much blood is needed?</article-title>
            <source>Vox Sang</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-21</page-range>
            <pub-id pub-id-type="pmid">21175652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allain</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Carneiro-Proietti</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lopes da Silva</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Proietti</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Reesink</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-transmitted infectious diseases.</article-title>
            <source>Biologicals</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-7</page-range>
            <pub-id pub-id-type="pmid">19231236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagner</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-transmitted bacterial infection: risks, sources and interventions.</article-title>
            <source>Vox Sang</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-63</page-range>
            <pub-id pub-id-type="pmid">15078249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brecher</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Bacterial contamination of blood components.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>195</fpage>
            <page-range>195-204</page-range>
            <pub-id pub-id-type="pmid">15653826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-transmitted babesiosis: is it time to screen the blood supply?</article-title>
            <source>Curr Opin Hematol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>573</fpage>
            <page-range>573-580</page-range>
            <pub-id pub-id-type="pmid">27537475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brecher</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Validation of BacT/ALERT plastic culture bottles for use in testing of whole-blood-derived leukoreduced platelet-rich-plasma-derived platelets.</article-title>
            <source>Transfusion</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>1174</fpage>
            <page-range>1174-8</page-range>
            <pub-id pub-id-type="pmid">15265121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eder</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Dy</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>DeMerse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Herron</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Apheresis technology correlates with bacterial contamination of platelets and reported septic transfusion reactions.</article-title>
            <source>Transfusion</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>12</issue>
            <fpage>2969</fpage>
            <page-range>2969-2976</page-range>
            <pub-id pub-id-type="pmid">28880363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Neal</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Bacterial contamination of platelets for transfusion: strategies for prevention.</article-title>
            <source>Crit Care</source>
            <year>2018</year>
            <month>Oct</month>
            <day>27</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>271</fpage>
            <pub-id pub-id-type="pmid">30367640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Identification of transfusion-transmitted hepatitis A through postdonation information in Korea: results of an HAV lookback (2007-2012).</article-title>
            <source>Vox Sang</source>
            <year>2018</year>
            <month>Jul</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">30003551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matheny</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kingery</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis A.</article-title>
            <source>Am Fam Physician</source>
            <year>2012</year>
            <month>Dec</month>
            <day>01</day>
            <volume>86</volume>
            <issue>11</issue>
            <fpage>1027</fpage>
            <page-range>1027-34; quiz 1010-2</page-range>
            <pub-id pub-id-type="pmid">23198670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Candotti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Assennato</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Laperche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Allain</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Levicnik-Stezinar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose.</article-title>
            <source>Gut</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>313</fpage>
            <page-range>313-321</page-range>
            <pub-id pub-id-type="pmid">29959168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis B: the virus and disease.</article-title>
            <source>Hepatology</source>
            <year>2009</year>
            <month>May</month>
            <volume>49</volume>
            <issue>5 Suppl</issue>
            <fpage>S13</fpage>
            <page-range>S13-21</page-range>
            <pub-id pub-id-type="pmid">19399811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ribeiro Barbosa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sousa Bezerra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carvalho-Costa</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Pimentel de Azevedo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lopes Flores</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baima Colares</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Malta Lima</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lampe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Melo Villar</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cross-Sectional Study to Determine the Prevalence of Hepatitis B and C Virus Infection in High Risk Groups in the Northeast Region of Brazil.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2017</year>
            <month>Jul</month>
            <day>17</day>
            <volume>14</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">28714924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zein</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of hepatitis C virus genotypes.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>223</fpage>
            <page-range>223-35</page-range>
            <pub-id pub-id-type="pmid">10755999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharp</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Origins of HIV and the AIDS pandemic.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>a006841</fpage>
            <pub-id pub-id-type="pmid">22229120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahieux</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gessain</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adult T-cell leukemia/lymphoma and HTLV-1.</article-title>
            <source>Curr Hematol Malig Rep</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>257</fpage>
            <page-range>257-64</page-range>
            <pub-id pub-id-type="pmid">20425378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Mendoza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aguilera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Requena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Lejarazu</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Pir&#x000f3;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roc</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trevi&#x000f1;o</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benito</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Alonso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aguinaga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Costa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Calder&#x000f3;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eir&#x000f3;s</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sauleda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barreiro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soriano</surname>
                <given-names>V</given-names>
              </name>
              <collab>Spanish HTLV Network</collab>
            </person-group>
            <article-title>Human T-lymphotropic virus type 1 infection and disease in Spain.</article-title>
            <source>AIDS</source>
            <year>2017</year>
            <month>Jul</month>
            <day>31</day>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1653</fpage>
            <page-range>1653-1663</page-range>
            <pub-id pub-id-type="pmid">28700391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cristiano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pupella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liumbruno</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>West Nile Virus in Europe and Safety of Blood Transfusion.</article-title>
            <source>Transfus Med Hemother</source>
            <year>2016</year>
            <month>May</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>158</fpage>
            <page-range>158-67</page-range>
            <pub-id pub-id-type="pmid">27403087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batista-Dos-Santos</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>DRC</given-names>
              </name>
              <name>
                <surname>Raiol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cabral</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Feio</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>P&#x000f3;voa</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ribeiro-Dos-Santos</surname>
                <given-names>&#x000c2;</given-names>
              </name>
            </person-group>
            <article-title>Strategy to improve malaria surveillance system preventing transfusion-transmitted malaria in blood banks using molecular diagnostic.</article-title>
            <source>Malar J</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>344</fpage>
            <pub-id pub-id-type="pmid">30285750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sayama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Furui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takakura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ishinoda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Momose</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsubayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Satake</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Seroprevalence of Trypanosoma cruzi infection among at-risk blood donors in Japan.</article-title>
            <source>Transfusion</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>287</fpage>
            <page-range>287-294</page-range>
            <pub-id pub-id-type="pmid">30474861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vamvakas</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Blajchman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Apr</month>
            <day>09</day>
            <volume>113</volume>
            <issue>15</issue>
            <fpage>3406</fpage>
            <page-range>3406-17</page-range>
            <pub-id pub-id-type="pmid">19188662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleinman</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Harpool</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Vanderpool</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Custer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wiltbank</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tomasulo</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Two-year experience with aerobic culturing of apheresis and whole blood-derived platelets.</article-title>
            <source>Transfusion</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>10</issue>
            <fpage>1787</fpage>
            <page-range>1787-94</page-range>
            <pub-id pub-id-type="pmid">17002636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hillyer</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Josephson</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Blajchman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vostal</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2003</year>
            <fpage>575</fpage>
            <page-range>575-89</page-range>
            <pub-id pub-id-type="pmid">14633800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Glynn</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kleinman</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Caglioti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>MP</given-names>
              </name>
              <collab>National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group</collab>
            </person-group>
            <article-title>Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Aug</month>
            <day>19</day>
            <volume>351</volume>
            <issue>8</issue>
            <fpage>760</fpage>
            <page-range>760-8</page-range>
            <pub-id pub-id-type="pmid">15317889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Notari</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population.</article-title>
            <source>Transfusion</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>975</fpage>
            <page-range>975-9</page-range>
            <pub-id pub-id-type="pmid">12385406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Swinkels</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Gulick</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <chapter-title>HIV and AIDS</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">30521281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Territo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vaqar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <chapter-title>HIV Prophylaxis (Archived)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30521273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steele</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Notari</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Reik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Custer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <collab>Transfusion-Transmissible Infections Monitoring System (TTIMS)</collab>
            </person-group>
            <article-title>HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men.</article-title>
            <source>Transfusion</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>839</fpage>
            <page-range>839-850</page-range>
            <pub-id pub-id-type="pmid">33460470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Crowder</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Notari</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016.</article-title>
            <source>Transfus Med Rev</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-93</page-range>
            <pub-id pub-id-type="pmid">32178888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stramer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations.</article-title>
            <source>Transfus Med Rev</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-28</page-range>
            <pub-id pub-id-type="pmid">21871776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez-Sanz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berzosa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>FF</given-names>
              </name>
            </person-group>
            <article-title>Updates on Malaria Epidemiology and Prevention Strategies.</article-title>
            <source>Curr Infect Dis Rep</source>
            <year>2023</year>
            <month>Jun</month>
            <day>08</day>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">37361492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Witteman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sundaravel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larocca</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Goldsztajn</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A case of HTLV-1 associated adult T-cell lymphoma presenting with cutaneous lesions and tropical spastic paresis.</article-title>
            <source>Intractable Rare Dis Res</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-64</page-range>
            <pub-id pub-id-type="pmid">29552450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Devare</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Seroprevalence of HTLV-1/2 Among Voluntary Blood Donors in Vietnam.</article-title>
            <source>AIDS Res Hum Retroviruses</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>376</fpage>
            <page-range>376-381</page-range>
            <pub-id pub-id-type="pmid">30565470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cl&#x000e1;udia Freitas Lidani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Kozlowski</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Luz</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Messias-Reason</surname>
                <given-names>IJ</given-names>
              </name>
            </person-group>
            <article-title>Case Report: High Mannose-Binding Lectin Serum Determined by <italic>MBL2</italic> Genotype and Risk for Clinical Progression to Chagasic Cardiomyopathy: A Case Report of Three Patients.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-96</page-range>
            <pub-id pub-id-type="pmid">30526728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velati</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roman&#x000f2;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fomiatti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baruffi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zanetti</surname>
                <given-names>AR</given-names>
              </name>
              <collab>SIMTI Research Group</collab>
            </person-group>
            <article-title>Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.</article-title>
            <source>Transfusion</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>10</issue>
            <fpage>2205</fpage>
            <page-range>2205-13</page-range>
            <pub-id pub-id-type="pmid">18631163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>HTLV screening of blood donors using chemiluminescence immunoassay in three major provincial blood centers of China.</article-title>
            <source>BMC Infect Dis</source>
            <year>2020</year>
            <month>Aug</month>
            <day>06</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>581</fpage>
            <pub-id pub-id-type="pmid">32762656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>Gde A</given-names>
              </name>
              <name>
                <surname>Louzada-Neto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>Vde F</given-names>
              </name>
              <name>
                <surname>Ferreira-Silva</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>de Moraes-Souza</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Performance of six diagnostic tests to screen for Chagas disease in blood banks andprevalence of Trypanosoma cruzi infection among donors with inconclusive serologyscreening based on the analysis of epidemiological variables.</article-title>
            <source>Rev Bras Hematol Hemoter</source>
            <year>2012</year>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>292</fpage>
            <page-range>292-7</page-range>
            <pub-id pub-id-type="pmid">23049443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seltsam</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pathogen Inactivation of Cellular Blood Products-An Additional Safety Layer in Transfusion Medicine.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2017</year>
            <volume>4</volume>
            <fpage>219</fpage>
            <pub-id pub-id-type="pmid">29255710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindholm</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Annen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ramsey</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Approaches to minimize infection risk in blood banking and transfusion practice.</article-title>
            <source>Infect Disord Drug Targets</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-56</page-range>
            <pub-id pub-id-type="pmid">21303341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashley</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>The duration of Plasmodium falciparum infections.</article-title>
            <source>Malar J</source>
            <year>2014</year>
            <month>Dec</month>
            <day>16</day>
            <volume>13</volume>
            <fpage>500</fpage>
            <pub-id pub-id-type="pmid">25515943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fattovich</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bortolotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.</article-title>
            <source>J Hepatol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>335</fpage>
            <page-range>335-52</page-range>
            <pub-id pub-id-type="pmid">18096267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mathis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Erin Staples</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lindsey</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Surveillance for West Nile virus disease - United States, 2009-2018.</article-title>
            <source>Am J Transplant</source>
            <year>2021</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>1959</fpage>
            <page-range>1959-1974</page-range>
            <pub-id pub-id-type="pmid">33939278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Omari</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heffess</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolpow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bourque</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Acute transverse myelitis in West Nile Virus, a rare neurological presentation.</article-title>
            <source>IDCases</source>
            <year>2021</year>
            <volume>24</volume>
            <fpage>e01104</fpage>
            <pub-id pub-id-type="pmid">33868926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almhanna</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Palanichamy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sil</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Unilateral brachial plexopathy associated with West Nile virus meningoencephalitis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2003</year>
            <month>Jun</month>
            <day>15</day>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>1629</fpage>
            <page-range>1629-30</page-range>
            <pub-id pub-id-type="pmid">12802774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Bartt</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Acute anterior radiculitis associated with West Nile virus infection.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>74</volume>
            <issue>6</issue>
            <fpage>823</fpage>
            <page-range>823-5</page-range>
            <pub-id pub-id-type="pmid">12754368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>da Silva</surname>
                <given-names>IRF</given-names>
              </name>
              <name>
                <surname>Frontera</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bispo de Filippis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>OJMD</given-names>
              </name>
              <collab>RIO-GBS-ZIKV Research Group</collab>
            </person-group>
            <article-title>Neurologic Complications Associated With the Zika Virus in Brazilian Adults.</article-title>
            <source>JAMA Neurol</source>
            <year>2017</year>
            <month>Oct</month>
            <day>01</day>
            <volume>74</volume>
            <issue>10</issue>
            <fpage>1190</fpage>
            <page-range>1190-1198</page-range>
            <pub-id pub-id-type="pmid">28806453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000e9;charles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Poullain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Deschamps</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mathon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Landais</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Breurec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lannuzel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acute myelitis due to Zika virus infection.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Apr</month>
            <day>02</day>
            <volume>387</volume>
            <issue>10026</issue>
            <fpage>1481</fpage>
            <pub-id pub-id-type="pmid">26946926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartzmann</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Ramalho</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Neder</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vilar</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Ayub-Ferreira</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Romeiro</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Takayanagui</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Dos Santos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figueiredo</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Arena</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sim&#x000f5;es</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Zika Virus Meningoencephalitis in an Immunocompromised Patient.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>92</volume>
            <issue>3</issue>
            <fpage>460</fpage>
            <page-range>460-466</page-range>
            <pub-id pub-id-type="pmid">28259231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nunes</surname>
                <given-names>MCP</given-names>
              </name>
              <name>
                <surname>Beaton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Acquatella</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bern</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Echeverr&#x000ed;a</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Dutra</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Gascon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morillo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Oliveira-Filho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>ALP</given-names>
              </name>
              <name>
                <surname>Marin-Neto</surname>
                <given-names>JA</given-names>
              </name>
              <collab>American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Stroke Council</collab>
            </person-group>
            <article-title>Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Sep</month>
            <day>18</day>
            <volume>138</volume>
            <issue>12</issue>
            <fpage>e169</fpage>
            <page-range>e169-e209</page-range>
            <pub-id pub-id-type="pmid">30354432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <article-title>Severe malaria.</article-title>
            <source>Trop Med Int Health</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>19 Suppl 1</volume>
            <fpage>7</fpage>
            <page-range>7-131</page-range>
            <pub-id pub-id-type="pmid">25214480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fran&#x000e7;a</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Pompilio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pontes</surname>
                <given-names>ERJC</given-names>
              </name>
              <name>
                <surname>de Oliveira</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>LOR</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>MCA</given-names>
              </name>
              <name>
                <surname>Fujimori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lima-J&#x000fa;nior</surname>
                <given-names>MSDC</given-names>
              </name>
              <name>
                <surname>Matos</surname>
                <given-names>MFC</given-names>
              </name>
              <name>
                <surname>Dorval</surname>
                <given-names>MEMC</given-names>
              </name>
            </person-group>
            <article-title>Leishmania infection in blood donors: A new challenge in leishmaniasis transmission?</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e0198199</fpage>
            <pub-id pub-id-type="pmid">29902188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30468.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alhumaidan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Westley</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Esteva</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berardi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-transmitted anaplasmosis from leukoreduced red blood cells.</article-title>
            <source>Transfusion</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>181</fpage>
            <page-range>181-6</page-range>
            <pub-id pub-id-type="pmid">22563784</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
